The cost effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data

被引：0
|
作者：
Kobelt, G.
Andlin-Sobocki, P.
Collantes-Estevez, E.
Gratacos-Masmitja, J.
Pocovi, A.
Mulero-Mendoza, J.
机构：
[1] European Hlth Econ, Stockholm, Sweden
[2] Stockholm Hlth Econ, Stockholm, Sweden
[3] Hosp Reina Sofia, Cordoba, Spain
[4] Hosp Sabadell, Barcelona, Spain
[5] Schering Plough Corp, Madrid, Spain
[6] Clin Puerta Hierro, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 283
页数：2
相关论文
共 50 条
  • [31] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial
    Braun, J
    Brandt, J
    Listing, J
    Zink, A
    Alten, R
    Golder, W
    Gromica-Ihle, E
    Kellner, H
    Krause, A
    Schneider, M
    Sörensen, H
    Zeidler, H
    Thriene, W
    Sieper, J
    LANCET, 2002, 359 (9313): : 1187 - 1193
  • [32] Therapies in ankylosing spondylitis-from clinical trials to clinical practice
    Tahir, Hasan
    RHEUMATOLOGY, 2018, 57 : 23 - 28
  • [33] VALIDATION OF THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) AND EFFECTIVENESS OF INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS OVER 4 YEARS
    Rahman, P.
    Choquette, D.
    Khraishi, M.
    Bensen, W.
    Shaikh, S.
    Sholter, D.
    Sheriff, M.
    Rampakakis, E.
    Sampalis, J. S.
    Nantel, F.
    Otawa, S.
    Lehman, A.
    Shawi, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 725 - 725
  • [34] VALIDATION OF THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) AND EFFECTIVENESS OF INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS OVER 4 YEARS
    Rahman, P.
    Choquette, D.
    Khraishi, M.
    Bensen, W. G.
    Shaikh, S. A.
    Sholter, D.
    Sheriff, M.
    Rampakakis, E.
    Sampalis, J. S.
    Nantel, F.
    Otawa, S.
    Lehman, A. J.
    Shawi, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 828 - 829
  • [35] Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis
    Venetsanopoulou, Aliki I.
    Voulgari, Paraskevi V.
    Alamanos, Yannis
    Papadopoulos, Christos G.
    Markatseli, Theodora E.
    Drosos, Alexandros A.
    RHEUMATOLOGY INTERNATIONAL, 2007, 27 (10) : 935 - 939
  • [36] Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis
    Aliki I. Venetsanopoulou
    Paraskevi V. Voulgari
    Yannis Alamanos
    Christos G. Papadopoulos
    Theodora E. Markatseli
    Alexandros A. Drosos
    Rheumatology International, 2007, 27 : 935 - 939
  • [37] CLINICAL EFFICACY AND SAFETY OF INFLIXIMAB - FIRST RESULTS AFTER A DECADE OF CONTINUOUS TREATMENT IN ANKYLOSING SPONDYLITIS
    Baraliakos, X.
    Listing, J.
    Fritz, C.
    Haibel, H.
    Alten, R.
    Burmester, G.
    Krause, A.
    Schewe, S.
    Schneider, M.
    Soerensen, H.
    Schmidt, R.
    Sieper, J.
    Braun, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 252 - 252
  • [38] Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply
    Wailoo, A.
    Bansback, N.
    Chilcott, J.
    RHEUMATOLOGY, 2008, 47 (10) : 1590 - 1590
  • [39] Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study
    Marzo-Ortega, H
    McGonagle, D
    Jarrett, S
    Haugeberg, G
    Hensor, E
    O'Connor, P
    Tan, AL
    Conaghan, PG
    Greenstein, A
    Emery, P
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (11) : 1568 - 1575
  • [40] Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece
    Gourzoulidis, George
    Solakidi, Argyro
    Psarra, Marina
    Nikitopoulou, Eleni
    Tzanetakos, Charalampos
    CLINICAL DRUG INVESTIGATION, 2024, 44 (01) : 59 - 69
12345